cyclosporine A (SCAI-001) / SCAI Therap - LARVOL DELTA

Quintessence of currently approved and upcoming treatments for dry eye disease. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS® [cyclosporine 0.05% ophthalmic emulsion], VEVYE® [cyclosporine 0.1% ophthalmic solution], and CEQUA™ [cyclosporine 0.09% ophthalmic solution]), XIIDRA® (lifitegrast), a leukocyte function-associated antigen-1 (LFA-1)/intracellular adhesion molecule-1(ICAM-1) inhibitor, EYSUVIS™ (loteprednol etabonate ophthalmic suspension 0.25%), a corticosteroid, and MIEBO™ (perfluorohexyloctane ophthalmic solution), a semifluorinated alkane. TYRVAYA™ (varenicline solution nasal spray), a cholinergic agonist, is another formulation approved for the treatment of the signs and symptoms of DED...Cyclosporine formulations TJO-087 (cyclosporine A nanoemulsion 0.08%), SCAI-001 eye drops (cyclosporine 0.01%, 0.02%) are being evaluated against RESTASIS® and other approved treatments. The potential treatments being assessed include..."

Journal • Review • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome • ICAM1

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis (clinicaltrials.gov) - P2 | N=116 | Completed | Sponsor: SCAI Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis (clinicaltrials.gov) - P2 | N=116 | Active, not recruiting | Sponsor: SCAI Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Dry Eye Disease • Ophthalmology

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: SCAI Therapeutics

New P2 trial • Dry Eye Disease • Ophthalmology